CLINICAL_TRIALS
trial_result
· 2021-08-05
Clinical Trial Update: Study of Evobrutinib in Participants With RMS [Phase 3]
Summary
Phase 3 trial of evobrutinib in relapsing-remitting multiple sclerosis was terminated; results posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2021-08-05